Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479522 | 0.83 | HCRTR1 (0.37) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479438 | 0.82 | IDO1 (0.43) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479658 | 0.80 | HCRTR1 (0.40) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479259 | 0.78 | GPBAR1 (0.39) | HCRTR1HCRTR2IDO1 | |
| SCHEMBL31479832 | 0.76 | HCRTR1 (0.40) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479628 | 0.76 | HCRTR1 (0.41) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479308 | 0.75 | HCRTR1 (0.39) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479205 | 0.74 | HCRTR1 (0.40) | HCRTR1HCRTR2KCNH2MEN1KMT2A | |
| SCHEMBL31479873 | 0.72 | HCRTR1 (0.41) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL31479328 | 0.72 | HCRTR1 (0.43) | HCRTR1HCRTR2KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |